KPKerstin E. Peterson

Kerstin E. Peterson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kerstin E. Peterson has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bivalent Inhibitor Development for a Dynamic Epigenetic Tandem Reader Protein Using a Combinatorial Histone Code

    by Joseph E. McPherson, Molly S. Sneddon, Richard K. Begyinah, Kesavan Babu, Kerstin E. Peterson, Ryan F. Friess, Thomas G. Smith, Natalia Y. Tretyakova, Marcus Fischer, William C.K. Pomerantz

    Epigenetic readers are a class of proteins that recognize specific chemical modifications on histones to differentially regulate gene expression. Aberrant expression of readers can drive the progression of many diseases and cancers, making this protein class viable therapeutic targets. Understanding the landscape of histone modifications recognized by reader domains, and the structural mechanisms that drive these molecular recognition events, is crucial for guiding the design of pharmaceutically relevant chemical probes. BPTF contains a plant homeodomain (PHD) finger and tandem bromodomain (BRD). Here, we expand upon previous studies that found the BPTF BRD can engage acetyllysine modifications on the N-terminus of histone H3. We uncover H3K4me 3 K14ac as the specific modifications recognized by the PHD-BRD cassette, which is confirmed by crystallography. Using orthogonal methods, our work explores how these modifications can be read cooperatively, including in cis. We report the first experimental evidence proposing a ligand-induced conformational change between the two reader domains of BPTF, supporting previous computational approaches that have predicted a macromolecular rearrangement. We leverage these structural insights to rationally design a peptide-small molecule conjugate MJ-1 that inhibits both domains of BPTF and overcomes ligandability challenges associated with PHD-finger-containing proteins. The results presented here elucidate the molecular basis of the bivalent recognition of multiply modified histone H3 by BPTF and provide structural insight for developing compounds targeting the PHD finger of BPTF for therapeutic applications.

  • Open Access

    Development of a Lysine‐Reactive Targeted Covalent Inhibitor for the P300/CBP‐Associated Factor Bromodomain Through Structure‐Based Design

    by Richard R. Ede, Kerstin E. Peterson, Richard K. Begyinah, Irin P. Tom, Jason M. Ochoada, Molly S. Sneddon, Ana Katrina Y. Tiu, Marcus Fischer, Anang A. Shelat, William C. K. Pomerantz

    Epigenetics is defined by changes in heritable phenotypes that do not involve a change in DNA sequence. P300/CBP‐associated factor (PCAF) is an important epigenetic regulatory protein that can alter chromatin through a histone acetyltransferase domain, while also serving as an epigenetic reader through a C‐terminal bromodomain. PCAF promotes the transcription of the HIV‐1 genome and is implicated in the development of glioblastoma. The currently reported PCAF inhibitors are non‐covalent and require high concentration to maintain target occupancy. Here, we explore a new approach using covalent inhibition. Starting with a lead scaffold (BZ1), test‐molecules were rationally designed for selectively targeting PCAF by installing lysine‐reactive groups onto the lead scaffold to enable covalent bond formation with the nonconserved lysine residue in the PCAF bromodomain. The inhibition, selectivity, and kinetic properties ( k inact / K I ) of these molecules were evaluated using intact protein mass spectrometry, while biophysical and cellular data were employed to verify the covalent mechanism and in‐cell target engagement. After optimization, we developed the first PCAF covalent inhibitor, 10 , which labeled PCAF covalently in vitro and engages PCAF in cells. The covalent inhibitor, 10 , represents a useful starting point for future inhibitor optimization and heterobifunctional molecule development.

  • BPTF Target Engagement by Acetylated H2A.Z Photoaffinity Probes

    by Kerstin E. Peterson, Noelle M. Olson, Dani J. Dahlseid, Jacklyn M. Artymiuk, Luke Erber, Francisca N. L. Vitorino, Renee Dean, Joseph W. Landry, Natalia Y. Tretyakova, Benjamin A. Garcia, et al.

    Histone variant H2A.Z has been increasingly associated with cancer progression, including cancers characterized by the dysregulated function of the epigenetic reader protein BPTF (bromodomain and PHD finger containing transcription factor). Despite this association, a direct interaction between acetylated H2A.Z and BPTF has not been validated in a physiological context, given the weak bromodomain-histone tail affinity. Here, we developed photoaffinity acetylated histone probes based on differentially acetylated H2A.Z isoforms I and II with an N-terminal diazirine and a C-terminal biotin tag for covalently capturing and enriching BPTF and new interactors. Photo-crosslinking experiments followed by SDS-PAGE revealed that recombinant BPTF bromodomain (BPTF BD) directly interacts with both isoforms of H2A.Z in an affinity-dependent and acetyl-lysine binding pocket-specific manner. In nuclear lysates prepared from A549 non-small cell lung cancer cells, acetylated H2A.Z isoform probes enriched endogenous BPTF as a photo-crosslinking target, but to a lesser extent than the canonical partner, H4K16ac. Finally, to determine the natural acetylation patterns of H2A.Z in a human cancer cell line, we used bottom-up proteomics to quantify the levels and patterns of acetylation on H2A.Z from A549 cells. Mono- and diacetylation were the predominant acetylation patterns identified, with patterns containing acetylation sites K4ac, K7ac, K11ac, and K15ac. These results indicate that our photoaffinity probes can capture transient epigenetic protein-protein interactions, while optimization of conditions for interactome analysis of these transient interactions will be necessary for identifying additional epigenetic regulators of H2A.Z.